In Vivo Therapeutic Effect of Cathepsin L Inhibitor (CatL-inh) on T1D in CY-treated NOD Mice.
(A, B) The blood glucose and urine glucose levels were monitored weekly. Data are shown as means ± s.d. of 4 or 5 mice in each group. *, P<0.05, and **, P<0.01. CY-treated mice versus CatL-inh-treated mice. Results are representative of 4 or 5 mice in each group. (C, D, E, F, G, H) Histopathological analysis of islets control (prediabetic) (C), CY-treated (D, E, F) and CY+CatL-inh-treated (G, H) NOD mice. Results are representative of 4 or 5 mice in each group. (I) Histological score of islets from control (n = 5), CY-treated (n = 4) and CY+CatL-inh-treated (n = 5) NOD mice. Data are shown as histological score of individual islets.